A recent study discusses the development of small molecule drugs targeting immune checkpoints as a promising alternative to traditional antibody-based therapies in cancer treatment. These small molecule inhibitors offer advantages such as better tissue penetration, oral bioavailability, and pharmacokinetic properties. Examples include BMS-202 and CA-170, which block PD-L1 and PD-1 interactions, and YPD-29B, which promotes PD-L1 degradation. The study highlights the potential of combining small molecule ICIs with other therapies to enhance treatment efficacy. Overall, small molecule ICIs could revolutionize cancer treatment by offering more effective and accessible options for patients. Further research and clinical trials are needed to establish these drugs in modern cancer therapy.
Source link
Advancing immune checkpoint inhibitors for cancer
